Document is current
Any future updates will be listed below
-
Authors
Jutzi, Jonas S. https://orcid.org/0000-0002-1977-153X
Crosse, Edie
Kim, Chulwoo J.
van Gasteren, Bob
Laurore, Charles
Rolles, Benjamin https://orcid.org/0000-0002-7393-861X
Kramer, Frederike
Tishena, Anastasia
Rocha, Azucena V.
Wazir, Mohammed
Weeks, Lachelle D. https://orcid.org/0000-0001-8726-6212
How, Joan https://orcid.org/0000-0002-6421-0117
Stahl, Maximilian
Luskin, Marlise R. https://orcid.org/0000-0002-5781-4529
Lindsley, R. Coleman https://orcid.org/0000-0001-9822-806X
Pozdnyakova, Olga https://orcid.org/0000-0001-8376-0344
Rai, Sumit
Graubert, Timothy A.
Bradley, Robert K. https://orcid.org/0000-0002-8046-1063
Mullally, Ann
Marneth, Anna E. https://orcid.org/0000-0001-9065-0581
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-20-1-0904)
U.S. Department of Defense (W81XWH2110909)
Radboud Universitair Medisch Centrum (Hypatia)
Deutsche Krebshilfe (70114570)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL131835)
Starr Foundation (I15-0026)
- License Information
-
More Information
Article History
Received: 12 May 2025
Revised: 19 December 2025
Accepted: 9 February 2026
First Online: 26 February 2026
Competing interests
: JSJ is currently an employee of Merck. MS served on the advisory board for Novartis, Kymera, Sierra Oncology, GSK, Rigel, BMS, Sobi, and Syndax, Kura; consulted for Boston Consulting, GLG, and Dedham group; and participated in CME activity for Novartis, Curis Oncology, Haymarket Media, and Clinical Care Options, and is a member of the Medical Safety Monitoring Board for Keros Pharmaceuticals. AM has received research funding from Morphic and has consulted for Cellarity.
